TY - JOUR
AB - AHFS firstRelease™ ® ™ AHFS firstRelease Warnings and Precautions. Infusion-related Reactions. Infusion-related reactions, Brand Information: Rezzayo including flushing, sensation of warmth, urticaria, nausea, and chest tightness, have been observed in clinical trials Introduction with rezafungin. If these reactions occur, slow or pause the Rezafungin acetate is an echinocandin antifungal agent. infusion and restart at a lower rate. Photosensitivity. Rezafungin may cause photosensitivity. Uses Patients should be advised to use protection from sun exposure Rezafungin acetate has the following uses: Rezafungin is and other sources of UV radiation during rezafungin treatment. indicated in patients 18 years of age or older who have limited Hepatic Adverse Reactions. Abnormalities in liver or no alternative options for the treatment of candidemia tests have been seen in clinical trial patients treated with and invasive candidiasis. Approval of this indication is based rezafungin. In some patients with serious underlying med- on limited clinical safety and efficacy data for the drug. ical conditions who were receiving multiple concomitant Specimens for culture and other laboratory data (e.g., medications along with rezafungin, clinically significant histopathology, non-culture diagnostics) should be obtained hepatic abnormalities have occurred. Monitor patients who prior to initiating antifungal therapy. Therapy may be initi- develop abnormal 
TI - Rezafungin Acetate
JO - American Journal of Health-System Pharmacy
DO - 10.1093/ajhp/zxad144
DA - 2023-07-20
UR - https://www.deepdyve.com/lp/oxford-university-press/rezafungin-acetate-gQ0yOiP5hP
SP - 1197
EP - 1198
VL - 80
IS - 18
DP - DeepDyve
ER -